- July 15, 2020
- Category: Healthcare and LifeSciences, Medical Diagnostics
Global Oncology Companion Diagnostic Market Size study, by Product & Service (Product and Services), by Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Immunohistochemistry (IHC), In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH) and Others), by Disease Type (Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Leukemia, Melanoma, Prostate Cancer and Others), by End User (Hospital, Pathology/Diagnostic Laboratory and Academic Medical Center) and Regional Forecasts 2020-2027
| Product Code: | HALMD_39779331 |
Chapter 1. Executive Summary 1.1. Market Snapshot 1.2. Global & Segmental Market Estimates & Forecasts, 2018-2027 (USD Billion) 1.2.1. Oncology Companion Diagnostic Market, by Region, 2018-2027 (USD Billion) 1.2.2. Oncology Companion Diagnostic Market, by Product & Service, 2018-2027 (USD Billion) 1.2.3. Oncology Companion Diagnostic Market, by Technology, 2018-2027 (USD Billion) 1.2.4. Oncology Companion Diagnostic Market, by Disease Type, 2018-2027 (USD Billion) 1.2.5. Oncology Companion Diagnostic Market, by End Use, 2018-2027 (USD Billion) 1.3. Key Trends 1.4. Estimation Methodology 1.5. Research Assumption Chapter 2. Global Oncology Companion Diagnostic Market Definition and Scope 2.1. Objective of the Study 2.2. Market Definition & Scope 2.2.1. Scope of the Study 2.2.2. Industry Evolution 2.3. Years Considered for the Study 2.4. Currency Conversion Rates Chapter 3. Global Oncology Companion Diagnostic Market Dynamics 3.1. Oncology Companion Diagnostic Market Impact Analysis (2018-2027) 3.1.1. Market Drivers 3.1.2. Market Challenges 3.1.3. Market Opportunities Chapter 4. Global Oncology Companion Diagnostic Market: Industry Analysis 4.1. Porter’s 5 Force Model 4.1.1. Bargaining Power of Suppliers 4.1.2. Bargaining Power of Buyers 4.1.3. Threat of New Entrants 4.1.4. Threat of Substitutes 4.1.5. Competitive Rivalry 4.1.6. Futuristic Approach to Porter’s 5 Force Model (2017-2027) 4.2. PEST Analysis 4.2.1. Political 4.2.2. Economical 4.2.3. Social 4.2.4. Technological 4.3. Investment Adoption Model 4.4. Analyst Recommendation & Conclusion Chapter 5. Global Oncology Companion Diagnostic Market, by Product & Service 5.1. Market Snapshot 5.2. Global Oncology Companion Diagnostic Market by Product & Service, Performance - Potential Analysis 5.3. Global Oncology Companion Diagnostic Market Estimates & Forecasts by Product & Service 2017-2027 (USD Billion) 5.4. Oncology Companion Diagnostic Market, Sub Segment Analysis 5.4.1. Product 5.4.2. Services Chapter 6. Global Oncology Companion Diagnostic Market, by Technology 6.1. Market Snapshot 6.2. Global Oncology Companion Diagnostic Market by Technology, Performance - Potential Analysis 6.3. Global Oncology Companion Diagnostic Market Estimates & Forecasts by Technology 2017-2027 (USD Billion) 6.4. Oncology Companion Diagnostic Market, Sub Segment Analysis 6.4.1. Polymerase Chain Reaction (PCR) 6.4.2. Next-Generation Sequencing (NGS) 6.4.3. Immunohistochemistry (IHC) 6.4.4. In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH) 6.4.5. Others Chapter 7. Global Oncology Companion Diagnostic Market, by Disease Type 7.1. Market Snapshot 7.2. Global Oncology Companion Diagnostic Market by Disease Type, Performance - Potential Analysis 7.3. Global Oncology Companion Diagnostic Market Estimates & Forecasts by Disease Type 2017-2027 (USD Billion) 7.4. Oncology Companion Diagnostic Market, Sub Segment Analysis 7.4.1. Breast Cancer 7.4.2. Non-Small Cell Lung Cancer 7.4.3. Colorectal Cancer 7.4.4. Leukemia 7.4.5. Melanoma 7.4.6. Prostate Cancer 7.4.7. Others Chapter 8. Global Oncology Companion Diagnostic Market, by End Use 8.1. Market Snapshot 8.2. Global Oncology Companion Diagnostic Market by End Use, Performance - Potential Analysis 8.3. Global Oncology Companion Diagnostic Market Estimates & Forecasts by End Use 2017-2027 (USD Billion) 8.4. Oncology Companion Diagnostic Market, Sub Segment Analysis 8.4.1. Hospital 8.4.2. Pathology/Diagnostic Laboratory 8.4.3. Academic Medical Center Chapter 9. Global Oncology Companion Diagnostic Market, Regional Analysis 9.1. Oncology Companion Diagnostic Market, Regional Market Snapshot 9.2. North America Oncology Companion Diagnostic Market 9.2.1.1. U.S. Oncology Companion Diagnostic Market 9.2.1.2. Product & Service breakdown estimates & forecasts, 2017-2027 9.2.1.3. Technology breakdown estimates & forecasts, 2017-2027 9.2.1.4. Disease Type breakdown estimates & forecasts, 2017-2027 9.2.1.5. End Use breakdown estimates & forecasts, 2017-2027 9.2.2. Canada Oncology Companion Diagnostic Market 9.3. Europe Oncology Companion Diagnostic Market Snapshot 9.3.1. U.K. Oncology Companion Diagnostic Market 9.3.2. Germany Oncology Companion Diagnostic Market 9.3.3. France Oncology Companion Diagnostic Market 9.3.4. Spain Oncology Companion Diagnostic Market 9.3.5. Italy Oncology Companion Diagnostic Market 9.3.6. Rest of Europe Oncology Companion Diagnostic Market 9.4. Asia-Pacific Oncology Companion Diagnostic Market Snapshot 9.4.1. China Oncology Companion Diagnostic Market 9.4.2. India Oncology Companion Diagnostic Market 9.4.3. Japan Oncology Companion Diagnostic Market 9.4.4. Australia Oncology Companion Diagnostic Market 9.4.5. South Korea Oncology Companion Diagnostic Market 9.4.6. Rest of Asia Pacific Oncology Companion Diagnostic Market 9.5. Latin America Oncology Companion Diagnostic Market Snapshot 9.5.1. Brazil Oncology Companion Diagnostic Market 9.5.2. Mexico Oncology Companion Diagnostic Market 9.6. Rest of The World Oncology Companion Diagnostic Market Chapter 10. Competitive Intelligence 10.1. Top Market Strategies 10.2. Company Profiles 10.2.1. Agilent Technologies, Inc. 10.2.1.1. Key Information 10.2.1.2. Overview 10.2.1.3. Financial (Subject to Data Availability) 10.2.1.4. Product Summary 10.2.1.5. Recent Developments 10.2.2. Illumina, Inc. 10.2.3. QIAGEN N.V. 10.2.4. Thermo Fisher Scientific, Inc. 10.2.5. F. Hoffmann-La Roche Ltd. 10.2.6. ARUP Laboratories 10.2.7. Abbott 10.2.8. Myriad Genetics, Inc. 10.2.9. bioMérieux SA 10.2.10. Invivoscribe, Inc. Chapter 11. Research Process 11.1. Research Process 11.1.1. Data Mining 11.1.2. Analysis 11.1.3. Market Estimation 11.1.4. Validation 11.1.5. Publishing 11.2. Research Attributes 11.3. Research Assumption
Global Oncology Companion Diagnostic Market is valued approximately at USD 2.2 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 12.7% over the forecast period 2020-2027. Oncology companion diagnostic is an in vitro medical device that provides information for the use of multiple drug or biological oncology products. This diagnostic test helps a health care professional to analyze and determine, whether an oncology or particular therapeutic product is valuable to patients and can outweigh any potential serious side effects or risks. The rising awareness for the advantages of companion diagnostics, growing need for targeted therapy, increasing global incidence of cancer and growing application areas of companion diagnostics are the few factors responsible for growth of the market over the forecast period. As per the Our World in Data Organization, breast cancer is the most prevalent form of cancer with an estimated number of about 17 million people with breast cancer in 2017. Further, as per the source, in 2018, about 2 million new cases were registered breast cancer worldwide. As per the American cancer society, breast cancer is the second leading cause of cancer-related deaths in women across the globe.
Also, according to the World Health Organization (WHO), the total new cases of liver cancer were reported 841,080 in 2018 and an estimated 781, 631 people died due to liver cancer, globally. Further increasing R&D expenditure in pharmaceutical industry for the introduction of better and beneficial drugs for patients will drive the market growth. For instance: as per Statista, the global research and development spending in pharmaceutical industry was USD 186 billion in 2019 and had experienced totaled USD 136 billion in 2012. Also, it is expected to rise by USD 233 billion spending of global research and development in pharmaceutical industry in 2026. However, high cost of companion diagnostic tests and uncertain reimbursement scenario in different regions are the major factors restraining the growth of global Oncology Companion Diagnostic market during the forecast period.
The regional analysis of global Oncology Companion Diagnostic market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. Asia Pacific is the leading/significant region across the world owing to the high incidence of cancer, increasing proteomics & genomics research, growing research funding, rising investments by pharmaceutical and biotechnology companies, and growing awareness about personalized therapeutics in several APAC countries.
Major market player included in this report are:
Agilent Technologies, Inc.
Illumina, Inc.
QIAGEN N.V.
Thermo Fisher Scientific, Inc.
F. Hoffmann-La Roche Ltd.
ARUP Laboratories
Abbott
Myriad Genetics, Inc.
bioMérieux SA
Invivoscribe, Inc.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Product & Service:
Product
Services
By Technology:
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Immunohistochemistry (IHC)
In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
Others
By Disease Type:
Breast Cancer
Non-Small Cell Lung Cancer
Colorectal Cancer
Leukemia
Melanoma
Prostate Cancer
Others
By End Use:
Hospital
Pathology/Diagnostic Laboratory
Academic Medical Center
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year – 2017, 2018
Base year – 2019
Forecast period – 2020 to 2027
Target Audience of the Global Oncology Companion Diagnostic Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors